A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
- Disease/Condition
- Plaque Psoriasis
- Drug/Device/Intervention
- JNJ-77242113
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Janssen Research & Development, LLC
- Location
- Fort Smith,Alpharetta,Rolling Meadows,Plainfield,Lake Charles,Fort Gratiot,New Brighton,Saint Joseph,Omaha,East Windsor,Boardman,Portland,Arlington,Pflugerville,San Antonio,Mill Creek,Taipei, Taiwan,United States of America
- Phase
- Phase 3
- Start date
- Oct 12, 2023
- End date
- May 31, 2027
- Enrollment
- 300 participants
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (=) 2 Grade Improvement From Baseline at Week 16
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque
 psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of
 the feet).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06095102
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06095102 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Research & Development, LLC and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.